Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome

Author(s): Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang, Xiaohui Zhou*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 25 , 2021

Become EABM
Become Reviewer
Call for Editor


Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction, and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins, anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor, phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically. These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective to treat this condition.

Keywords: Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 22 March, 2021
Page: [2861 - 2871]
Pages: 11
DOI: 10.2174/1381612827666210322125054
Price: $65

Article Metrics

PDF: 147